cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.48323/jn2er-y9832
title: Effect of α-amplexichromanol (27a) on lipid mediator formation in zymosan induced murine peritonitis

description: Neukirch, K. et al. Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation. J Med Chem 64, 11496-11526 (2021). https://doi.org/10.1021/acs.jmedchem.1c00806
CD-1 mice received 27a or zileuton, with DMSO (2%) in saline (0.5 mL) as a vehicle for i.p. administration and carboxymethylcellulose (0.5%) in 10% Tween 20 (0.5 mL) as a vehicle for p.o. administration. Zymosan (2 mg/mL insaline, i.p., 0.5 mL, Sigma-Aldrich) was injected at 30 min (i.p.) or 60min (p.o.) post compound administration. Mice were sacrificed by inhalation of CO2 after another 30 min to determine LTC4 levels, lipid mediator profiles, metabolites, and vascular permeability and after 4 h to analyze LTB4 levels and cell infiltration. Plasma and peritoneal exudates were collected, and cells were counted in exudates after trypan blue staining. Compound 27a, its metabolites, and lipid mediators were extracted and analyzed by UPLC-MS/MS as described in Neukirch et al., 2021.
DOI: 10.48323/e2mex-dex05
title: Concentration of leukotrienes in lung and plasma of mice with ovalbumin induced asthma

description: Neukirch, K. et al. Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation. J Med Chem 64, 11496-11526 (2021). https://doi.org/10.1021/acs.jmedchem.1c00806
BALB/c mice received 27a (p.o.) or vehicle (0.5% carboxymethylcellulose in 10% Tween 20; 0.5 mL) on days 0 and 7, 1 h (p.o) before being sensitized to ovalbumin (OVA) (100 μg adsorbed to 3.3 mg of aluminum hydroxide gel, s.c., Sigma-Aldrich). Mice were sacrificed on days 1, 3, 8, 10, or 21 to collect lung and plasma. LTB4, and LTB4 isomers were analyzed in plasma and lung homogenates by UPLC-MS/MS as described in Neukirch et al., 2021. Lung tissue (100 mg/mL) was homogenized in PBS pH 7.4 at 4°C for 1−2 min using an Omni tissue homogenizer (Omni, Kennesaw, GA).
DOI: 10.48323/fsbjn-mha09
title: Concentration of α-amplexichromanol (27a) in lung and plasma of mice with ovalbumin induced asthma

description: Neukirch, K. et al. Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation. J Med Chem 64, 11496-11526 (2021). https://doi.org/10.1021/acs.jmedchem.1c00806
BALB/c mice received 27a (p.o.) or vehicle (0.5% carboxymethylcellulose in 10% Tween 20; 0.5 mL) on days 0 and 7, 1 h (p.o) before being sensitized to ovalbumin (100 μg adsorbed to 3.3 mg of aluminum hydroxide gel, s.c., Sigma-Aldrich). Mice were sacrificed on days 1, 3, 8, 10, or 21 to collect lung and plasma. Compound 27a was analyzed in plasma and lung homogenates by UPLC-MS/MS as described in Neukirch et al., 2021. Lung tissue (100 mg/mL) was homogenized in PBS pH 7.4 at 4°C for 1−2 min using an Omni tissue homogenizer (Omni, Kennesaw, GA).
DOI: 10.23729/4fb60b0f-fe7b-4337-b5b0-af3a13f11b6d
title: Understanding Selective Hydrogenation of Phenylacetylene on PdAg Single Atom Alloy: DFT Insights on Molecule Size and Surface Ensemble Effects

description: This archive contains the optimized structures and the NEB-paths used in the article. The structures for all the molecules in gas phase are in ./Molecules. The adsorption structures for acetylene, phenylacetylene and diphenylacetylene and hydrogenated derivatives thereof are present in ./Acetylene, ./Phenylacetylene and ./Diphenylacetylene, respectively. Each folder contains a subfolder for Ag(111), Pd(111) and PdAg(111) surfaces. In addition, there is a folder ./Pd dimer sublayer for the adsorption structures and the reaction pathways for all the reactant molecules on Pd dimer ensemble and Pd sublayer surfaces discussed in the main article. All trajectories are in the ASE ”traj”-format.
DOI: 10.48323/fypv2-49c97
title: Metabolism of α-amplexichromanol (27a) in a human liver-on-chip model

description: Neukirch, K. et al. Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation. J Med Chem 64, 11496-11526 (2021). https://doi.org/10.1021/acs.jmedchem.1c00806
Biochips were made from polystyrene by injection molding and were equipped with a poly(ethylene terephthalate) (PET) membrane (TRAKETCH, thickness: 12μm; pore diameter: 8μm; pore density: 1×10^5 pores/cm2; Sabeu, Radeberg, Germany) that was integrated in the upper and lower parts of the biochip by heat-sealing with the bulk material. The top and bottom sides of the biochips and channels were sealed with an extruded PS bonding foil (thickness: 125 μm) by a low-temperature bonding method. The upper and lower parts of the biochips were assembled using a double-sided adhesive film, and the chip surface was hydrophilized by oxygen plasma treatment to facilitate cell adhesion and prevent air bubble formation within the chambers and channels. HUVECs were isolated from human umbilical cord veins and cultivated in an endothelial cell growth medium MV (Promocell, Heidelberg, Germany) with penicillin (100 U/mL) / streptomycin (100 μg/mL, GE Healthcare) up to passage 4. On reaching 95% confluence, cells were sub-cultured at a density of 1.5×10^4 cells/cm2. HepaRG cells (Biopredic International, Rennes, France) were grown in William's medium E (Biochrom, Berlin, Germany) with 10% FCS, 5 μg/mL insulin (Sigma-Aldrich), 2 mM glutamine (Thermofisher Scientific), 50 μM hydrocortisone-hemisuccinate (Sigma-Aldrich), and penicillin (100 U/mL) / streptomycin (100μg/mL, GE Healthcare) at 37°C and 5% CO2 for 14 days prior to differentiation with 2% DMSO for another 14 days. The medium was changed every 3−4 days, and differentiated cells were used up to 4weeks. The liver-on-chip was prepared by seeding HUVECs (top: 3×10^5, bottom: 1.5×10^5) in an endothelial cell growth medium MV on top of the membrane in the upper chamber and on the bottom of the membrane in the lower chamber, giving the cells 3−4 h to adhere before flipping the chip upside and seeding the bottom layer. After 2 days, differentiated HepaRG cells (3×10^5) were seeded on top of the lower and on the bottom of the upper membrane in a hepatocyte culture medium with hydrocortisone-hemisuccinate adjusted to 5 μM for 24 h at 37°C and 5% CO2. The medium between the two membranes was renewed, and the vehicle (DMSO), 12a, or 27a were added. After incubation for 48 h at 37°C and 5% CO2, the medium was collected and the system was washed with 500 μL of methanol. 12a, 27a, and their metabolites were extracted from the combined fractions and analyzed by UPLC-MS/MS as described in Neukirch et al., 2021.
DOI: 10.57992/nmrxiv.p32.s185
title: Pulegone
DOI: 10.57992/nmrxiv.p32.s185.d794
title: Pulegone[6]
DOI: 10.57992/nmrxiv.p32.s185.d795
title: Pulegone[1]
DOI: 10.57992/nmrxiv.p32.s185.d796
title: Pulegone[3]
DOI: 10.57992/nmrxiv.p32.s185.d797
title: Pulegone[2]
DOI: 10.57992/nmrxiv.p32.s185.d798
title: Pulegone[4]
DOI: 10.57992/nmrxiv.p32.s185.d799
title: Pulegone[5]
DOI: 10.22008/fk2/k1mxcl/91sarc
title: T250_Topographic_Index_400dpi.pdf

description: :unav
DOI: 10.22008/fk2/k1mxcl/msoytw
title: T250_Topographic_Index_400dpi.tif

description: :unav
DOI: 10.22008/fk2/k1mxcl
title: Index: Topographic maps of North and North-East Greenland

description: Topographic maps of North and North-East Greenland 1:250 000 Data collected from aerial photographs at nomimal scale 1:150 000 by the Danish Geodetic Institute in the period 1978 - 1987; rectified using ground control and aerotriangulation from the National Survey and Cadastre (KMS) (permission A.200/87). The map sheet extent and the numbers of the map sheets are based on the two map series at scale 1:250 000 and 1:100 000 of KMS. Geodetic reference: WGS84, Projection: Universal Transverse Mercator, zone 24 N.
DOI: 10.48784/11568050-56fd-44e9-b1e8-2bf7649153a4
title: A validation of ADO drought indices SPI and SPEI in Slovenia
title: A validation of ADO drought indices SPI and SPEI in Slovenia

description: Drought indices are essential for tracking and warning of the possible drought related effects, impacts and outcomes (WMO and GWP, 2016). The use of a specific drought index in this manner requires a prior assessment of the index performance in detecting and monitoring different types of drought. Agricultural drought affects plants and crops, sometimes resulting in extensive crop failure. As agricultural drought is particularly relevant for the Alpine region and the Slovenian case study area, we investigated the ability of SPI and SPEI to detect agricultural drought through validation against annual yield data for several crops and types of grassland, averaged to statistical regions (NUTS3 level). Prior to evaluating indices against yield data, we evaluated SPI and SPEI values calculated from ERA5 reanalyses against SPI and SPEI values calculated from ground observations at representative meteorological stations in Slovenia in order to learn whether the indices calculated in the Alpine domain are relevant on a national level.
DOI: 10.21223/vg1mhd/vzufsb
title: RandomForestToClassifyLateBlightSeverity.rar

description: :unav
DOI: 10.21223/vg1mhd
title: Random Forest to classify the severity of Late blight in potato crops

description: It is a Random Forest algorithm developed in Python to classify 21 categories of Late blight severity, where the class 0 is soil and from 1 to 21 were symptom score measured by experts in field. It use as inputs aerial multispectral images acquired of two potato trials.
DOI: 10.6084/m9.figshare.24886239
title: <b><i>Sanguinoderma infundibulare</i></b>

description: Genomic annotation of <i>Sanguinoderma infundibulare</i>
DOI: 10.17638/datacat.liverpool.ac.uk/938
title: AGILE: Candidate specific trial protocol 2 (CST2): EIDD-2801 (molnupiravir) Primary Analysis

description: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment. (UoL001542B)

The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on the basis of data from unvaccinated adults. The randomised, placebo-controlled, double-blind, phase 2 trial (AGILE CST-2) aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and unvaccinated individuals with COVID-19. The primary outcome was the time from randomisation to SARS-CoV-2 PCR negativity on nasopharyngeal swabs, analysed by use of a Bayesian Cox proportional hazards model for estimating the probability of a superior virological response (hazard ratio [HR]&gt;1) for molnupiravir versus placebo. This trial is registered in ClinicalTrials.gov (NCT04746183), and the ISRCTN registry (ISRCTN27106947).

We undertook a dose-escalating, open-label, randomized-controlled (standard-of-care) Bayesian adaptive Phase I trial to evaluate the safety and optimal dose of molnupiravir in patients with early symptomatic infection.
 
�-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. 

Molnupiravir induces lethal error catastrophe in SARS-CoV-2. How this drug-induced mechanism of action might impact the emergence of resistance mutations is unclear. To investigate this, we used samples from the AGILE CST-2. We describe the pre-specified exploratory virological endpoint of CST-2, to determine the possible genomic changes in SARS-CoV-2 induced by molnupiravir treatment.
description: These data were used for the trial primary analysis detailed in the associated publications.
DOI: 10.48784/c74035a7-121c-4213-b702-cea35a0ca4d0
title: Report on existing monitoring platforms and potential data for the integration into ADO
title: Report on existing monitoring platforms and potential data for the integration into ADO

description: The purpose of this report is to prepare a foundation for this working process. An overview of the state of drought observation and detection in the Alpine region has been prepared, which will also serve as basis for its upgrade or extension to the entire Alpine area. The state of the art analysis prepared by project partners (at least one per participating country) was conducted by uniform questionnaire that was circulated among ADO project partners covering four topics: drought monitoring approach, drought-information platforms, the regional & EU drought monitoring approach, and potential drought indices in ADO.
DOI: 10.6084/m9.figshare.24886248
title: Domcke-2020

description: Processed anndata file of the human cell atlas of fetal chromatin accessibility (Domcke et al. <i>Science</i> 370.6518 (2020): eaba7612). This is the anndata file provided in GLUE (Cao et al. <i>Nat Biotechnol</i> <b>40</b>, 1458–1466 (2022)), downloaded from: http://download.gao-lab.org/GLUE/dataset/Domcke-2020.h5ad.
DOI: 10.22008/fk2/fiqp9s/rmltzq
title: T250_Washington_Land_80v1_400dpi.tif

description: :unav
DOI: 10.22008/fk2/fiqp9s
title: 80 V.1 Washington Land. Topographic map, 1:250 000

description: Topographic map of Greenland, 1:250 000, 80 V.1 Washington Land. 400 dpi. Coloured maps at 1:250 000 with contour interval 100 m. A set of 53 digital maps covers North and North-East Greenland from lnglefield Land in the west to Scoresby Sund in the east. One additional sheet provides an index map and a legend. The maps show the usual range of physiographic features, viz. coasts, rivers, lakes and ice. They are coloured with a 100 m contour interval over both land and ice, and with selected spot heights in metres. They have been drawn at the Survey from air photographs using Kort & Matrikelstyrelsen (KMS) ground control points and aerotriangulation. Map projection is Universal Transverse Mercator, zone 24. The maps are a sequel to a set of geological sheets at the same scale but with four extra sheets covering lnglefield Land and Humboldt Gletscher.
DOI: 10.22008/fk2/fiqp9s/lyv8gm
title: T250_Washington_Land_80v1_400dpi.pdf

description: :unav
DOI: 10.22008/fk2/zobbyl/sobpkp
title: T250_Warming_Land_81v2_400dpi.pdf

description: :unav
DOI: 10.22008/fk2/zobbyl
title: 81 V.2 Warming Land. Topographic map, 1:250 000

description: Topographic map of Greenland, 1:250 000, 81 V.2 Warming Land. 400 dpi. Coloured maps at 1:250 000 with contour interval 100 m. A set of 53 digital maps covers North and North-East Greenland from lnglefield Land in the west to Scoresby Sund in the east. One additional sheet provides an index map and a legend. The maps show the usual range of physiographic features, viz. coasts, rivers, lakes and ice. They are coloured with a 100 m contour interval over both land and ice, and with selected spot heights in metres. They have been drawn at the Survey from air photographs using Kort & Matrikelstyrelsen (KMS) ground control points and aerotriangulation. Map projection is Universal Transverse Mercator, zone 24. The maps are a sequel to a set of geological sheets at the same scale but with four extra sheets covering lnglefield Land and Humboldt Gletscher.
DOI: 10.22008/fk2/zobbyl/k8okxl
title: T250_Warming_Land_81v2_400dpi.tif

description: :unav
DOI: 10.57992/nmrxiv.p33
title: CENAPTNMR
DOI: 10.57992/nmrxiv.p33.s186
title: Lupeol 900MHz 400MHz CDCl3 NMR data
DOI: 10.57992/nmrxiv.p33.s186.d800
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_13C.jdf]
DOI: 10.57992/nmrxiv.p33.s186.d801
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_HMBC_900.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d802
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_13CdeptQ.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d803
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_HMBC.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d804
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_400_gCOSY.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d805
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_COSY.jdf]
DOI: 10.57992/nmrxiv.p33.s186.d806
title: Lupeol 900MHz 400MHz CDCl3 NMR data[5_Lupeol_HMBC]
DOI: 10.57992/nmrxiv.p33.s186.d807
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_400_1H.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d808
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_gCOSY.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d809
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_q1H.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d810
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_13C.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d811
title: Lupeol 900MHz 400MHz CDCl3 NMR data[2_Lupeol_gcosy]
DOI: 10.57992/nmrxiv.p33.s186.d812
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_qH.jdf]
DOI: 10.57992/nmrxiv.p33.s186.d813
title: Lupeol 900MHz 400MHz CDCl3 NMR data[4_Lupeol_HSQC]
DOI: 10.57992/nmrxiv.p33.s186.d814
title: Lupeol 900MHz 400MHz CDCl3 NMR data[1_Lupeol_1H]
DOI: 10.57992/nmrxiv.p33.s186.d815
title: Lupeol 900MHz 400MHz CDCl3 NMR data[3_Lupeol_13CdeptQ]
DOI: 10.57992/nmrxiv.p33.s186.d816
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_HMBC_ABS.jdf]
DOI: 10.57992/nmrxiv.p33.s186.d817
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_HSQC.jdf]
DOI: 10.57992/nmrxiv.p33.s186.d818
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_gHSQC.jdx]
DOI: 10.57992/nmrxiv.p33.s186.d819
title: Lupeol 900MHz 400MHz CDCl3 NMR data[Lupeol_LUPE01_400_HSQC.jdx]
DOI: 10.57992/nmrxiv.p33.s187
title: Apigenin annotated NMR 400MHz DMSOd6 data
DOI: 10.57992/nmrxiv.p33.s187.d820
title: Apigenin annotated NMR 400MHz DMSOd6 data[simulated_1H.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d821
title: Apigenin annotated NMR 400MHz DMSOd6 data[COSY.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d822
title: Apigenin annotated NMR 400MHz DMSOd6 data[1H.jdf]
DOI: 10.57992/nmrxiv.p33.s187.d823
title: Apigenin annotated NMR 400MHz DMSOd6 data[13C.jdf]
DOI: 10.57992/nmrxiv.p33.s187.d824
title: Apigenin annotated NMR 400MHz DMSOd6 data[HSQC.jdf]
DOI: 10.57992/nmrxiv.p33.s187.d825
title: Apigenin annotated NMR 400MHz DMSOd6 data[HMBC.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d826
title: Apigenin annotated NMR 400MHz DMSOd6 data[HSQC.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d827
title: Apigenin annotated NMR 400MHz DMSOd6 data[13C.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d828
title: Apigenin annotated NMR 400MHz DMSOd6 data[HMBC.jdf]
DOI: 10.57992/nmrxiv.p33.s187.d829
title: Apigenin annotated NMR 400MHz DMSOd6 data[1H.jdx]
DOI: 10.57992/nmrxiv.p33.s187.d830
title: Apigenin annotated NMR 400MHz DMSOd6 data[COSY.jdf]
DOI: 10.57992/nmrxiv.p33.s188
title: Rutin 400 MHz in DMSOd6 NMR data
DOI: 10.57992/nmrxiv.p33.s188.d831
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_qHNMR_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s188.d832
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_qHNMR_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s188.d833
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_HMBC_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s188.d834
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_HSQC_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s188.d835
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_COSY_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s188.d836
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_HMBC_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s188.d837
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_HSQC_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s188.d838
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_COSY_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s188.d839
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_13CNMR_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s188.d840
title: Rutin 400 MHz in DMSOd6 NMR data[Rutin_3080ug200uL_DMSOd6_13CNMR_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189
title: Caffeic acid 400 MHz in DMSOd6 NMR data
DOI: 10.57992/nmrxiv.p33.s189.d841
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_13CNMR_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189.d842
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_COSY_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189.d843
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_HSQC_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189.d844
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_13CNMR_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s189.d845
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_qHNMR_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189.d846
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_qHNMR_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s189.d847
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_COSY_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s189.d848
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_HMBC_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s189.d849
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_HMBC_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s189.d850
title: Caffeic acid 400 MHz in DMSOd6 NMR data[CaffeicAcid_3080ug200uL_DMSOd6_HSQC_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s190
title: Curcumin annotated NMR 400 MHz DMSOd6 data
DOI: 10.57992/nmrxiv.p33.s190.d851
title: Curcumin annotated NMR 400 MHz DMSOd6 data[HMBC.jdx]
DOI: 10.57992/nmrxiv.p33.s190.d852
title: Curcumin annotated NMR 400 MHz DMSOd6 data[COSY.jdx]
DOI: 10.57992/nmrxiv.p33.s190.d853
title: Curcumin annotated NMR 400 MHz DMSOd6 data[1H.jdx]
DOI: 10.57992/nmrxiv.p33.s190.d854
title: Curcumin annotated NMR 400 MHz DMSOd6 data[13C.jdf]
DOI: 10.57992/nmrxiv.p33.s190.d855
title: Curcumin annotated NMR 400 MHz DMSOd6 data[13C.jdx]
DOI: 10.57992/nmrxiv.p33.s190.d856
title: Curcumin annotated NMR 400 MHz DMSOd6 data[COSY.jdf]
DOI: 10.57992/nmrxiv.p33.s190.d857
title: Curcumin annotated NMR 400 MHz DMSOd6 data[HSQC.jdx]
DOI: 10.57992/nmrxiv.p33.s190.d858
title: Curcumin annotated NMR 400 MHz DMSOd6 data[HMBC.jdf]
DOI: 10.57992/nmrxiv.p33.s190.d859
title: Curcumin annotated NMR 400 MHz DMSOd6 data[HSQC.jdf]
DOI: 10.57992/nmrxiv.p33.s190.d860
title: Curcumin annotated NMR 400 MHz DMSOd6 data[1H.jdf]
DOI: 10.57992/nmrxiv.p33.s191
title: Berberine annotated NMR 400 MHz DMSOd6 data
DOI: 10.57992/nmrxiv.p33.s191.d861
title: Berberine annotated NMR 400 MHz DMSOd6 data[HSQC.jdf]
DOI: 10.57992/nmrxiv.p33.s191.d862
title: Berberine annotated NMR 400 MHz DMSOd6 data[COSY.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d863
title: Berberine annotated NMR 400 MHz DMSOd6 data[simulated_1H.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d864
title: Berberine annotated NMR 400 MHz DMSOd6 data[1H.jdf]
DOI: 10.57992/nmrxiv.p33.s191.d865
title: Berberine annotated NMR 400 MHz DMSOd6 data[13C.jdf]
DOI: 10.57992/nmrxiv.p33.s191.d866
title: Berberine annotated NMR 400 MHz DMSOd6 data[HSQC.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d867
title: Berberine annotated NMR 400 MHz DMSOd6 data[13C.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d868
title: Berberine annotated NMR 400 MHz DMSOd6 data[COSY.jdf]
DOI: 10.57992/nmrxiv.p33.s191.d869
title: Berberine annotated NMR 400 MHz DMSOd6 data[HMBC.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d870
title: Berberine annotated NMR 400 MHz DMSOd6 data[1H.jdx]
DOI: 10.57992/nmrxiv.p33.s191.d871
title: Berberine annotated NMR 400 MHz DMSOd6 data[HMBC.jdf]
DOI: 10.57992/nmrxiv.p33.s192
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data
DOI: 10.57992/nmrxiv.p33.s192.d872
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data[EpiCatechin_2880ug200uL_DMSOd6_HSQC_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s192.d873
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data[EpiCatechin_2880ug200uL_DMSOd6_COSY_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s192.d874
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data[EpiCatechin_2880ug200uL_DMSOd6_1H_400MHz_JDX.jdx]
DOI: 10.57992/nmrxiv.p33.s192.d875
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data[EpiCatechin_2880ug200uL_DMSOd6_COSY_400MHz_Jeol.jdf]
DOI: 10.57992/nmrxiv.p33.s192.d876
title: (-)-Epicatechin 400 MHz in DMSOd6 NMR data[EpiCatechin_2880ug200uL_DMSOd6_HMBC_400MHz_JDX.jdx]